Board of Directors

Paul L. Berns

Mr. Berns was appointed to the role of Anacor’s President and Chief Executive Officer in 2014. He has served as a member of our Board of Directors since 2012 and has served as Chairman of our Board of Directors since 2013. From September 2012 to March 2014, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From March 2006 to August 2012, Mr. Berns served as President and Chief Executive Officer, and member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns has been a director of Cellectar Biosciences, Inc. since November 2013, Jazz Pharmaceuticals, PLC since June 2010 and of XenoPort, Inc. since 2005. Mr. Berns received a B.S. in Economics from the University of Wisconsin.

Anders D. Hove, M.D.

Anders D. Hove, M.D. has served as a member of our Board since 2005. Dr. Hove is a general partner of Venrock Associates, a venture capital firm, which he joined in January 2004. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr. Hove is a member of the board of directors of a number of private companies. He received a M.Sc. from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Européen d'Administration des Affaires, or INSEAD.

Keith R. Leonard, Jr.

Mr. Leonard has served as a member of our board since 2014. He has more than 20 years of experience in the pharmaceutical industry and most recently served as President, Chief Executive Officer and a member of the board of directors of Kythera Biopharmaceuticals, Inc., a biopharmaceutical company that he co-founded, focused on discovering, developing and commercializing drugs for the aesthetic medicine market, from 2005 until its acquisition by Allergan plc in October 2015. From 1991 to 2004, Mr. Leonard held various positions at Amgen Inc., most recently as Senior Vice President and General Manager of Amgen Europe where he was responsible for all commercial operations in 28 European countries. Mr. Leonard previously served on the boards of Affymax, Inc. and ARYx Therapeutics, Inc. Mr. Leonard received a B.S. in Engineering from the University of California, Los Angeles, a B.A. in History from the University of Maryland, an M.S. in Engineering from the University of California, Berkeley, and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

Mark Leschly

Mark Leschly has served as a member of our Board since 2002. From 2002 until June 2013, Mr. Leschly served as our Chairman. Since July 1999, Mr. Leschly has been a managing partner with Rho Capital Partners, Inc., an investment and venture capital management company. In addition, since 2014, Mr. Leschly has been the owner and a managing member of Iconia, LLC, which primarily focused on providing brand management consulting services. From 1994 through 1999, Mr. Leschly was an Associate and then a general partner of HealthCare Ventures, L.P., a venture capital management company. Mr. Leschly previously served as a director of Verenium Corporation, NitroMed, Inc., Senomyx, Inc. and Tercica, Inc., and he is on the board of a number of private companies. Mr. Leschly received an A.B. from Harvard University and an M.B.A. from the Stanford Graduate School of Business.

William J. Rieflin

William J. Rieflin has served as our Independant Lead Director since May 2014 and as a member of our board since 2011. Since September 2010 he has been the Chief Executive Officer and a director of NGM Biopharmaceuticals, Inc., a biotechnology company. From 2004 until 2010, he served as President of XenoPort, Inc., a biotechnology company focused on the discovery and development of transported prodrugs. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, the most recent of which was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary. Amgen Inc., a biotechnology company, acquired Tularik in 2004. Mr. Rieflin is currently a director of XenoPort, Inc. and NGM Biopharmaceuticals, Inc. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.

Lucy Shapiro, Ph.D.

Lucy Shapiro, Ph.D., one of our co-founders, has served as a member of our Board since our inception in 2000. She is also the co-chair of our scientific advisory board. Dr. Shapiro, the Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center for Molecular and Genetic Medicine in the School of Medicine at Stanford University, has been at Stanford University since 1989. Dr. Shapiro is a Fellow of the American Association for the Advancement of Sciences and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. She was elected to the American Philosophical Society and received the Selman Waksman Award from the National Academy of Sciences in 2005 and in 2009 was given the Canada Gairdner International Award, considered one of the most prestigious awards in biomedical science. She was awarded the 2011 President's National Medal of Science by President Obama. In 2010, she was presented with the Abbott Lifetime Achievement Award. Dr. Shapiro is currently a non-executive director of Pacific Biosciences of California, Inc., and she was a non-executive director of GenProbe from 2008 to 2012 and of GlaxoSmithKline (GSK) from 2001 to 2006. She received a B.S. from Brooklyn College and a Ph.D. in molecular biology from the Albert Einstein School of Medicine.

Wendell Wierenga, Ph.D.

Wendell Wierenga, Ph.D. has served as a member of our board since 2014. Dr. Wierenga is a seasoned pharmaceutical executive with broad experience in all aspects of research, drug discovery and drug development. From June 2011 until February 2014, Dr. Wierenga served as Executive Vice President, Research and Development of Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. From 2007 until May 2011, he served as Executive Vice President, Research and Development of Ambit Biosciences Corporation. From 2003 to 2007, Dr. Wierenga served as Executive Vice President, Research and Development of Neurocrine Biosciences, Inc. From 2000 to 2003, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. From 1990 to 2000, Dr. Wierenga was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis, a division of Warner Lambert Co. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co. and its successor companies for 16 years in various positions, most recently as executive director of discovery research. In addition, Dr. Wierenga is a member of the boards of directors of Xenoport, Inc., Cytokinetics, Incorporated, Ocera Therapeutics, Inc., Apricus Biosciences, Inc. and Concert Pharmaceuticals, Inc. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University.